Structure of AG-636

dihydroorotate dehydrogenase inhibitor

in Ph. I for RR-lymphoma

from opt. of literature molecule

Mol. Cancer Ther., Oct. 20, 2020

Agios Pharmaceuticals, Cambridge, MA

AG-636 (Agios Pharmaceuticals dihydroorotate dehydrogenase (DHODH) inhibitor clinical candidate)


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.